In Table 1 of this article, the data in the column PICO 10 and 11 contain errors and the correct version provided below: The new PICO 10 is as follow: PICO 10: In patients with “non-infected neuropathic foot ulcers”, is the offloading obtained with surgical procedures preferable to that obtained with non-surgical interventions, to reduce the risk of adverse outcomes? PICO 11 modified as follow: “In diabetic patients with previous ulcers, is the use of therapeutic footwear with a rigid or semirigid sole preferable to standard of care footwear, to reduce the risk of adverse outcomes?” In Supplementary Materials, Table S3 reported for some PICOs a minimum studies follow-up threshold of 12 weeks. This is a typo; the actual threshold is 26 weeks for all studies on pharmacological/nonpharmacological interventions. Only for PICO with no trials with a follow-up of at least 26 weeks, the evidence review team will consider trial with a shorter duration (at least 12 weeks). No threshold will be considered for PICO on diagnostic assessments. The new PICO 10 is as follow: PICO 10: In patients with “non-infected neuropathic foot ulcers”, is the offloading obtained with surgical procedures preferable to that obtained with non-surgical interventions, to reduce the risk of adverse outcomes? PICO 11 modified as follow: “In diabetic patients with previous ulcers, is the use of therapeutic footwear with a rigid or semirigid sole preferable to standard of care footwear, to reduce the risk of adverse outcomes?” In Supplementary Materials, Table S3 reported for some PICOs a minimum studies follow-up threshold of 12 weeks. This is a typo; the actual threshold is 26 weeks for all studies on pharmacological/nonpharmacological interventions. Only for PICO with no trials with a follow-up of at least 26 weeks, the evidence review team will consider trial with a shorter duration (at least 12 weeks). No threshold will be considered for PICO on diagnostic assessments.
Monami, M., Scatena, A., Miranda, C., Monge, L., De Cassai, A., Volpe, A., et al. (2024). Correction to: Development of the Italian clinical practice guidelines for the treatment of diabetic foot syndrome: design and methodological aspects (Acta Diabetologica, (2023), 60, 11, (1449-1469), 10.1007/s00592-023-02150-8). ACTA DIABETOLOGICA, 61(6), 807-808 [10.1007/s00592-024-02263-8].
Correction to: Development of the Italian clinical practice guidelines for the treatment of diabetic foot syndrome: design and methodological aspects (Acta Diabetologica, (2023), 60, 11, (1449-1469), 10.1007/s00592-023-02150-8)
Gargiulo M.
;
2024
Abstract
In Table 1 of this article, the data in the column PICO 10 and 11 contain errors and the correct version provided below: The new PICO 10 is as follow: PICO 10: In patients with “non-infected neuropathic foot ulcers”, is the offloading obtained with surgical procedures preferable to that obtained with non-surgical interventions, to reduce the risk of adverse outcomes? PICO 11 modified as follow: “In diabetic patients with previous ulcers, is the use of therapeutic footwear with a rigid or semirigid sole preferable to standard of care footwear, to reduce the risk of adverse outcomes?” In Supplementary Materials, Table S3 reported for some PICOs a minimum studies follow-up threshold of 12 weeks. This is a typo; the actual threshold is 26 weeks for all studies on pharmacological/nonpharmacological interventions. Only for PICO with no trials with a follow-up of at least 26 weeks, the evidence review team will consider trial with a shorter duration (at least 12 weeks). No threshold will be considered for PICO on diagnostic assessments. The new PICO 10 is as follow: PICO 10: In patients with “non-infected neuropathic foot ulcers”, is the offloading obtained with surgical procedures preferable to that obtained with non-surgical interventions, to reduce the risk of adverse outcomes? PICO 11 modified as follow: “In diabetic patients with previous ulcers, is the use of therapeutic footwear with a rigid or semirigid sole preferable to standard of care footwear, to reduce the risk of adverse outcomes?” In Supplementary Materials, Table S3 reported for some PICOs a minimum studies follow-up threshold of 12 weeks. This is a typo; the actual threshold is 26 weeks for all studies on pharmacological/nonpharmacological interventions. Only for PICO with no trials with a follow-up of at least 26 weeks, the evidence review team will consider trial with a shorter duration (at least 12 weeks). No threshold will be considered for PICO on diagnostic assessments.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
